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Immunotherapy has transformed the treatment of melanoma patients. However, despite the
enormous promise of immunotherapy, a major fraction of patients with advanced melanoma
still succumb to this deadly disease. In addition, systemic immunotherapy can lead to relevant
toxicities. Therefore, it is an unmet need to identify the factors that modulate the outcome
and response to therapy of melanoma patients. One major factor accounting for individual
differences in the host response to cancer is the genetic makeup of the germline. A thorough
assessment of the role of germline genetics in melanoma outcome is lacking, partly because of
the difficulty in assessing the vast number of genetic variants present in the human population.
In this thesis, I describe the discovery of the impact of three highly prevalent variants of the
Apolipoprotein E (APOE) gene on melanoma progression and outcome. Using transgenic
human APOE mice, we found that mice expressing the APOE4 variant exhibit slower melanoma
progression and metastasis than APOE2 mice. The impact of APOE genotype on melanoma
progression was mediated by modulation of anti-melanoma immunity. APOE4 mice showed
enhanced activation of anti-tumor immunity relative to APOE2 mice, and T cell depletion
abrogated the impact of APOE genotype on melanoma progression.
Importantly, analysis of large-scale human melanoma data validated the impact of APOE
genotype on melanoma progression in humans. Amongst melanoma patients at high risk of
melanoma-associated death, carriers of the APOE2 variant showed worse survival outcomes
relative to APOE3 homozygotes and APOE4 carriers in two independent studies.
APOE genotype also impacted melanoma outcome in the context of anti-PD1 immunotherapy
in both mice and humans. Additionally, APOE4 mice derived robust benefit of pharmacologic
activation of liver-X-receptors, a class of transcription factors inducing APOE expression. In
contrast, APOE2 showed no treatment benefit, indicating that APOE genotype may serve as a
biomarker for response to LXR-agonistic immunotherapy.
Overall, our data describe the first example of highly common germline variants that modulate
the outcome of a common cancer type. These findings suggest APOE to be a potential
biomarker for outcome and therapy response in melanoma. More generally, our findings
suggest that common variants of the germline genetic makeup substantially modulate cancer
outcome and will likely be a cornerstone of precision cancer management.
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1 Introduction
1.1 Epidemiology and biology of melanoma
Malignant melanoma is a cancer arising from melanocytes, the pigment-producing cells found
in the skin and other tissues of the body. Because of its propensity to spread to distant organs,
melanoma is more dangerous than other types of skin cancer, such as squamous cell carcinoma
and basal cell carcinoma. The incidence of melanoma has increased 17-fold for men and 9-fold
for women between 1950 and 2007 (Geller et al., 2013), making it the fifth most common cancer
type in males and females in the United States in 2019 (National Cancer Institute). Globally,
the incidence of melanoma is approximately 1-25 per 100,000 individuals, with substantial
geographic and ethnic variation.
1.1.1 Risk factors for melanoma
The biggest risk factor for melanoma is environmental exposure to ultraviolet light (Elwood and
Jopson, 1997), which leads to DNA damage with a characteristic accumulation of cytosine
to thymine mutations (Lawrence et al., 2013). The risk for sporadic melanoma is modulated
by a number of prevalent germline variants with low penetrance, exemplified by the highly
polymorphic melanocortin 1 receptor (MC1R) gene. Individuals with fair skin exihibit increased
melanoma risk (Schadendorf et al., 2015).
While environmental factors are the most important risk factor in sporadic cases of melanoma,
germline genetic variations have been found in families with increased melanoma incidence
(Hayward, 2003). In familial cases, which account for 10 % of melanoma cases, germline
mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) locus are the most prevalent
genomic alteration (Kamb et al., 1994; FitzGerald et al., 1996). The CDKN2A locus encom-
passes two open reading frames, which encode the distinct tumor suppressors p16INK4A and
p14ARF, both of which regulate cell cycle transition. In addition to CDKN2A, germline mutations
have been identified in the CDK4, BAP1, POT1 and other genomic loci. However, the genetic
basis of a substantial fraction of familial melanomas remains unaccounted for (Schadendorf
et al., 2015).
1.1.2 Molecular landscape of melanoma
Hyperactivation of the mitogen-activated protein kinase (MAPK) pathway is a central molecular
feature of melanoma. The MAPK-pathway consists of the small GTPase RAS (HRAS, KRAS,
or NRAS), RAF kinase (ARAF, BRAF or CRAF), MAP/ERK kinase (MEK1 and MEK2) and
MAPK (MAPK1 and MAPK3). Activating mutations in components of the MAPK-signaling
pathway are present in approximately 75 % of melanomas: approximately 50 % of melanomas
harbor the BRAFV600E mutation, which results in ~700-fold increased activation of the pathway
relative to wildtype (Wan et al., 2004). Activating mutations of NRAS are present in ~25 %
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of all melanomas (The Cancer Genome Atlas Network, 2015). Of note, isolated activating
mutations of MAPK pathway components result in cellular senescence because of cellular
stress subsequent to MAPK-hyperactivation (Michaloglou et al., 2005). Therefore, additional
genetic aberrations are required for full malignant transformation. These codrivers comprise
additional activating mutations in oncogenes, such as in CDK4, CCND1 or KIT. The loss
of tumor suppressors can act as alternative codrivers, such as deletions and transcriptional
silencing of PTEN. Somatic deletions and transcriptional silencing of CDKN2A also occur in
sporadic melanoma, consistent with its frequent mutant germline status in familial melanoma
(The Cancer Genome Atlas Network, 2015).
1.1.3 Targeted therapy of melanoma
Given the addiction of melanoma to MAPK-signaling and the high frequency of BRAF and
NRAS mutations, targeting the MAPK pathway has been a promising approach to molecular-
guided therapy. Efforts to inhibit hyperactive mutant BRAF culminated in the approval of the
small molecule inhibitor vemurafenib for the treatment of metastatic melanoma. Vemurafenib
exhibits impressive response rates in over 80 % of melanoma patients (Chapman et al., 2011).
Unfortunately, however, responses to vemurafenib are short-lived, with most patients developing
resistance and eventual progression of the disease (Sosman et al., 2012). Resistance can
develop due to amplification of the mutant BRAFV600E locus (Shi et al., 2012), secondary
mutations downstream from BRAF (Nazarian et al., 2010), or activation of pathways other than
MAPK (Villanueva et al., 2010). In addition to vemurafenib, other inhibitors of BRAF as well as
inhibitors targeting other components of the MAPK pathway have been developed, such as the
MEK inhibitor trametinib. Combination therapy with both BRAF and MEK inhibition improves
response rates, but the majority of melanoma patients similarly experiences relapse and/or
progression under combination therapy (Robert et al., 2019), highlighting the need for additional
therapeutic modalities, as discussed below (see 1.2.3).
1.2 Anti-tumor immunity and its therapeutic modulation in melanoma
Cancer cells exhibit genomic alterations, which give rise to the expression of neoantigens
and antigens physiologically only expressed during development or in immune-privileged sites.
The altered antigen-profile of cancer cells enables immune cells to distinguish cancer cells
from physiological cells (Schumacher and Schreiber, 2015). The hypothesis that the immune
system has the capacity to fight cancer can be traced back to at least the 19th century, when
spontaneous regressions of cancer were noticed in patients that acquired erysipela infections.
William Coley exploited these findings therapeutically by treating bone cancer patients with
bacterial injections (Dobosz and Dziecia˛tkowski, 2019). However, it was not until 50 years later,
that Thomas and Burnet proposed the cancer immunosurveillance theory, according to which
lymphocytes identify and eliminate cancer cells. The work by Boon and colleagues provided
proof that in cancer patients, CD8+ T cells spontaneously exist that recognize cancer-specific
peptide-MHCI complexes (Boon et al., 1994). Rapid advances in immunology, mouse models,
and molecular biology firmly established the capacity of the immune system to ward off cancer
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(Dunn et al., 2004). A current model of how the immune system fights cancer is represented by
the tumor immunity cycle, as described below (1.2.1).
1.2.1 The tumor immunity cycle
The tumor immunity cycle describes the cascade of events that need to take place for the elimi-
nation of cancer cells by the immune system (Figure 1.1) (Chen and Mellman, 2013). The cycle
starts with tumor cells releasing antigens that get taken up by specialized antigen-presenting
cells of the immune system, most importantly dendritic cells (Roberts et al., 2016). Upon
antigen ingestion, antigen-presenting cells migrate to secondary lymphoid organs, such as
tumor-draining lymph nodes, where they present tumor-derived antigens on major histocom-
patibility complex (MHC) class I and class II molecules to naïve T cells. T cells whose T cell
receptor recognizes a specific antigen/MHC complex get primed and activated, resulting in
clonal expansion. Notably, for T cells to get activated and expand, antigen-presenting cells
need to present co-stimulatory molecules in addition to the antigen/MHC-complex. Such co-
stimulatory signaling comprises the interaction between B7 molecules (CD86 and CD80) on
dendritic cells with CD28 on T cells. Without co-stimulation, antigen presentation can induce
T regulatory cell responses rather than effector responses (Driessens et al., 2009). Upon
activation, T cells migrate to the tumor via the blood stream, where they recognize their cognate
antigen presented on MHC molecules of the tumor, and engage in an effector response. The
effector response leads to tumor cell killing via the secretion of cytokines and direct cell-cell
interactions, and thereby perpetuates the tumor immunity cycle. It is still a matter of debate to
which degree T cell priming can also take place within the tumor and alleviate the requirement
of dendritic cell migration to secondary lymphoid organs (Roberts et al., 2016; Thompson et al.,
2010).
1.2.2 The tumor immune microenvironment
Tumor cells, dendritic cells and T cells constitute the main components of the tumor immunity
cycle. However, multiple other factors modulate and participate in the immune response to
cancer. First, other cell types can assume certain functions of the tumor immunity cycle. For
example, natural killer cells (NK cells) are potent cytotoxic lymphocytes of the innate immune
system, which engage in tumor cell killing and cytokine secretion regulated by a suite of
activating, co-stimulatory and inhibitory receptors (Shimasaki et al., 2020). Second, other cell
types modulate the function of the tumor immunity cycle at different steps of the cascade. CD4+
T cells, which recognize specific antigens presented by MHCII molecules, can directly participate
in tumor cell killing (Kreiter et al., 2015). In addition, CD4+ T cells modulate the activity of CD8+
effector T cells, even in tumors not expressing MHCII molecules (Alspach et al., 2019). Multiple
other cell types exist in the highly heterogeneous tumor immune microenvironment, including
several myeloid cell types (Binnewies et al., 2018). Intratumoral myeloid cells exist across a
spectrum of differentiation and activation states (Broz and Krummel, 2015; Gabrilovich, 2017).
Importantly, many intratumoral myeloid cells, including poorly differentiated myeloid cells termed
myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), exert
pro-tumor functions. Myeloid cells can stimulate tumor progression by suppressing anti-tumor
3
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effector cells, as well as by stimulating angiogenesis and secreting protumoral survival factors
(Coussens et al., 1999; Ruffell et al., 2014; Sippel et al., 2011). Non-immune components
also modulate anti-cancer immunity, such as cancer-associated fibroblasts (Kumar et al., 2017;
Lakins et al., 2018) and vascular cells (Tian et al., 2017). The tumor microenvironment is highly
patient-specific; the factors that shape it and thereby modulate cancer and therapy outcome
are described below (see 1.3).
1.2.3 Immunotherapy of melanoma
In patients with cancer, the immune system has failed to provide protection from cancer progres-
sion, indicating that the tumor immunity cycle does not work efficiently. Specific targeting of the
rate-limiting step in the tumor immunity cycle offers the intriguing opportunity to reinvigorate anti-
cancer immunity. Before the advent of checkpoint inhibition therapy, dacarbazine chemotherapy
and high-dose interleukin-2 constituted the mainstay of melanoma therapy. Unfortunately,
these showed poor efficacy in patients with advanced disease and usually did not provide
curative outcomes (Pasquali et al., 2018). The therapy of melanoma was transformed by the
development of therapies targeting checkpoints of the immune response to cancer.
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a molecule expressed by T cells that
competes with CD28 for binding to B7 molecules on antigen-presenting cells (see 1.2.2). In
contrast to the stimulatory effects conferred by CD28, ligation of CTLA4 results in inhibition of
T cell profileration and activation (Krummel and Allison, 1995), thereby acting as a negative
checkpoint during T cell priming. Consistently, antibody-mediated inhibition of CTLA4 promotes
anti-tumor imunity (Leach et al., 1996). CTLA4 is also expressed on tumor-promoting regulatory
CD4+ T cells (Treg), and the efficacy of CTLA4 blockade is partially mediated by modulating
Treg function and abundance (Peggs et al., 2009). The CTLA4-blocking antibody ipilimumab
was approved for patients with advanced melanoma in 2011, leading to long-term survival in
~12 % of patients (Hodi et al., 2010; Robert et al., 2011).
Programmed cell death protein 1 (PD1) is another checkpoint molecule expressed by T cells
that limits their activation. The main ligand for PD1 is programmed death-ligand 1 (PD-L1),
which is expressed by a variety of cell types, including several immune subsets, cancer cells,
and vascular cells. Importantly, the PD1/PD-L1 checkpoint acts at a later stage of T cell
activation than CTLA4 by mainly regulating T cell effector functions after initial T cell priming
(Freeman et al., 2000). Notably, PD1 is also expressed by immune cell types other than T
cells, including macrophages, and inhibition of PD1 has been shown to also promote anti-tumor
activity in these non T cell populations (Gordon et al., 2017; Hsu et al., 2018). Two PD1-inhibiting
antibodies have been approved for melanoma treatment, nivolumab and pembrolizumab. They
exhibit more favorable efficacy and toxicity profiles than CTLA4 inhibitors, with impressive
overall response rates of ~30 – 40 % (Topalian et al., 2012; Hamid et al., 2013). Their reduced
toxicity relative to CTLA4 inhibition is likely due to the different mechanism of action, which
targets the more downstream T cell effector phase. The complementarity of the mechanisms of
action has prompted the assessment of combining CTLA4 and PD1 blockade, which further
improves efficiacy of the individual agents (Larkin et al., 2019). Of note, the inhibition of PD-L1
is also tested in cancer patients, but has not yet been approved for the treatment of melanoma
(Mariathasan et al., 2018). Inhibiting PD-L1 likely confers different effects from PD1 inhibition,
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since T cells also express PD-L1 which binds to B7 proteins (Butte et al., 2007). Additionally,
PD-L1 inhibition does not affect the interaction of PD1 with another ligand, PD-L2, whose
significance in cancer immunity warrants further assessment (Obeid et al., 2016; Lakins et al.,
2018).
In addition to the widely applied inhibition of the CTLA4 and PD1 checkpoints in melanoma
therapy, a range of alternative approaches have been explored to promote anti-tumor immunity.
Cancer vaccination is one of the best studied of these. It comprises the injection of cancer
derived antigenic peptides or proteins as well as the infusion of ex-vivo pulsed dendritic cells.
Unfortunately, the efficacy of cancer vaccination attempts has been poor, with an objective
response of < 5 % across multiple trials (Melero et al., 2014). However, it is possible that
improving dendritic cell activation, enhanced antigen selection, and refined patient selection
may increase the efficacy of cancer vaccination in the future (Carreno et al., 2015; Palucka
and Coussens, 2016). Adoptive T cell transfer constitutes another approach to enhance
anti-melanoma immunity. Different strategies use naturally occurring tumor-specific T cells
expanded ex-vivo as well as genetically engineered T cells transduced with either normal T
cell receptors or chimeric antigen receptor (Hunder et al., 2008; Rosenberg and Restifo, 2015).
One major limitation to the widespread use of T cell adoptive transfer is the laborious and
patient-specific process required for its application. Therefore, current efforts aim at generating
T cell products that can be employed across patients (Crowther et al., 2020). In addition, in
contrast to B cell neoplasias, in which cell-based therapies have been paradigm-changing, the
identification of cancer-specific neoantigens has been challenging (Rafiq et al., 2020). Lastly,
targeting of a multitude of other immune checkpoint molecules is currently undergoing clinical
testing (Marin-Acevedo et al., 2018).
Immunotherapy has transformed the prospect of patients with advanced melanoma. Moving
forward, the identification of new targets for immunotherapy as well as the combination of
different approaches, such as oncogene-targeted and immunotherapies hold promise to extend
the benefit to an increasing share of patients (Havel et al., 2019).
1.3 Determination of melanoma outcome
Despite the unprecedented success of immunotherapy in melanoma as outlined above (see
1.2.3), a large fraction of patients with advanced melanoma ultimately still succumb to their
disease (Larkin et al., 2019; Liu et al., 2019). Additionally, systemic therapy is associated with
relevant toxicities, such as immune-related adverse events in the case of checkpoint inhibition
(Hodi et al., 2010). For these reasons, it is critical to identify the factors that predict outcome of
melanoma patients with and without therapeutic intervention. These factors are related to the
tumor, the host, and the environment, as summarized below.
1.3.1 Modulators of melanoma immunotherapy
A major effect of immune checkpoint therapy consists of unleashing pre-existing immunity. It
is therefore not surprising that the degree of pre-existing anti-tumor immunity correlates with
the response to this therapeutic approach (Kim and Chen, 2016). Three basic immune profiles
can be distinguished according to the degree of immune infiltration in the tumor before therapy
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initiation: The immune-inflamed phenotype is characterized by infiltration of T cells into the
tumor; these patients exhibit the best therapy outcome (Herbst et al., 2014). In contrast, the
immune-excluded phenotype is characterized by accumulation of immune cells in stromal tissue
surrounding tumor cells without tumor penetration, and immune-desert tumors exhibit paucity of
T cells in the tumor and the surrounding stroma. Notably, the predictive value of T cell infiltration
for checkpoint therapy response is not universal: for example, there was no association in a
study assessing anti-PD1 therapy in a patient cohort in which a large fraction had previously
received anti-CTLA4 therapy (Riaz et al., 2017). Similarly, the expression of PD-L1, which
correlates with interferon signaling in the tumor microenvironment, has been shown to predict
for response in immune checkpoint inhibition in certain cases, but patients with low PD-L1
expression can also benefit (Topalian et al., 2012; Davis and Patel, 2019).
The existence of distinct immune profiles in patients poses the important question which fac-
tors determine the composition and functional state of the tumor microenvironment. Oncogenic
signaling is one major factor underlying the patient-specificity of the tumor microenvironment.
The impact of oncogenic signaling pathways on the state of the tumor immune microenviron-
ment is still incompletely understood, but associations have been shown for an increasing
number of frequently altered genomic loci, including p53 and KRAS (Pylayeva-Gupta et al.,
2012; Blagih et al., 2020). In melanoma, the BRAFV600E mutation described above increases
the expression of multiple cytokines that alter the phenotype of monocyte-derived dendritic cells
(Sumimoto et al., 2006). Tumors in the BRAFV600EPten-/- melanoma model exhibit constitutively
active WNT/β-catenin signaling, which suppresses the recruitment of CD103+ dendritic cells
via the inhibition of CCL4 production and thereby promotes cancer immune evasion (Spranger
et al., 2015). Moreover, loss of PTEN alone renders melanoma cells more resistant to cytotoxic
T cells and checkpoint therapy (Peng et al., 2016). Genomic alterations outside of oncogenes
and tumor suppressors have also been shown to modulate antigen presentation and cell death
as well as to exert immunosuppressive effects (Rooney et al., 2015).
T cells distinguish tumor cells from healthy cells due to the expression of tumor-associated
antigens. These comprise non-mutated self-antigens wich are aberrantly expressed or over-
expressed and neoantigens that arise as a consequence of somatic mutations. Consistently,
the overall mutational burden is one of the best predictors for response to checkpoint inhibition
so far (Snyder et al., 2014; Van Allen et al., 2015). Melanomas exhibit the highest mutational
burden of all human tumors, offering a potential explanation for the overall favorable outcome
of immunotherapy in this cancer type (Hodis et al., 2012). However, the association between
mutational burden and immunotherapy outcome is not robust enough for individual patient
stratification (Riaz et al., 2017; Liu et al., 2019). Heterogeneity is another characteristic of the
tumor that impacts response to immunotherapy, since increased heterogeneity increases the
likelihood of clonal tumor populations to evade the immune system. Consistently, the response
to immune checkpoint blockade is more favorable in melanoma patients with low intratumor
heterogeneity (McGranahan et al., 2016; Riaz et al., 2017).
Factors determined by the host also shape anti-tumor immunity. Recent research has
revealed a major impact of the microbiome composition on anti-tumor immunity (Zitvogel et al.,
2018). In addition, age, sex, and obesity affect anti-tumor immunity (Pitt et al., 2016; Galluzzi
et al., 2018). Importantly, germline variation also shapes patient-specific anti-tumor immunity,
and its impact will be described in more detail below (see 1.3.2).
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Lastly, several environmental factors participate in modulating the interplay between tumor
and the immune system, including infectious agents, exposure to sunlight, and pharmacological
agents (Chen and Mellman, 2017).
1.3.2 The role of germline variation in melanoma outcome
Variants of the germline genetic makeup are known to account for differences in the immune
response between individuals. For example, genotype-phenotype association studies have
identifed multiple single nucleotide polymorphisms (SNP) that modify activation of dendritic cells
and T cells in the contexts of infectious disease and autoimmunity (Parkes et al., 2013; Lee et al.,
2014; Raj et al., 2014; Ye et al., 2014; Cho and Feldman, 2015; Tian et al., 2017). It is therefore
plausible to assume that germline variations also impact anti-tumor immunity. Consistent
with this hypothesis, polymorphisms in FCGR3A, a gene encoding a receptor with roles in
antibody-dependent cell-mediated cytotoxicity, associate with outcome in melanoma patients
treated with ipilimumab (Arce Vargas et al., 2018). Polymorphism in genes encoding danger
sensing Toll-like receptors associate with survival in melanoma (Tittarelli et al., 2012; Gast et al.,
2011). In breast cancer, a loss-of-function polymorphism in the ATP-sensing P2RX7 receptor
that mediates dendritic cell activation predicts for worse metastasis-free survival (Ghiringhelli
et al., 2009). In the analysis of 1,535 patients with cancer treated with checkpoint blockade, a
larger diversity of the MHCI encoding genes associated with enhanced outcome, potentially
owing to the ability of the immune system to present a broader repertoire of tumor-associated
antigen-derived peptides (Chowell et al., 2018). A recent analysis of The Cancer Genome Atlas
(TCGA) study identified the association of certain SNPs with the degree of immune infiltration
in solid tumors (Shahamatdar et al., 2019). Additionally, targeted assessment revealed SNPs
known to modulate autoimmune disease to associate with outcome of checkpoint blockade
in melanoma (Chat et al., 2019). Therefore, multiple SNPs have been identified that shape
anti-melanoma immunity. However, a global assessment of the association of germline variation
and its causal role in modulating melanoma outcome is lacking.
1.4 The LXR/APOE-signaling axis
Apolipoprotein E (APOE) is a 34 kDa secreted glycoprotein that is produced mainly by the liver,
the central nervous system, and macrophages (Utermann et al., 1975; Holtzman et al., 2012;
Belloy et al., 2019). A major function of APOE is tied to its presence on lipoprotein particles,
whose uptake it facilitates by binding to members of the low-density lipoprotein receptor (LDLR)
family, which includes LDLR, LRP1, VLDLR, LRP2 (megalin), LRP8, LRP4, and LRP1b (Lane-
Donovan and Herz, 2017). Because of their expression in the brain, the interaction between
APOE and the LDLR, VLDLR, LRP1, and LRP8 receptors is best characterized (Mahley et al.,
1979; Holtzman et al., 2012).
In addition to its canonical role in lipid shuttling in organismal metabolism, several other
functions of APOE have been described (Martinez-Martínez et al., 2020). In immunity, APOE-
deficient mice have been shown to be susceptible to infections with intracellular bacteria and
virus (Ludewig et al., 2001; Martens et al., 2008; Toledo et al., 2015). Paradoxically, Apoe-
knockout mice exhibit hyperinflammation and chronic lymph node hypertrophy, but this was
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shown to be due to impaired migration of dendritic cells to lymph nodes as well as impaired
egress of lymphocytes from lymph nodes, explaining immune dysfunction in these mice (Angeli
et al., 2004; Tay et al., 2019). The mechanism through which APOE modulates immunity is
incompletely understood and seems context-specific (Zhang et al., 2010). Consistent with
a role in promoting immunity, APOE has been shown to mediate uptake of lipid antigens
by antigen-presenting cells and subsequent priming of natural killer T cells (van den Elzen
et al., 2005). Apoe-/- mice also exhibit reduced delayed-type hypersensitivity (Laskowitz et al.,
2000). Conversely, consistent with APOE exerting immunosuppressive functions, a recent
study indicated Apoe-deficiency to result in enhanced MHCII-mediated antigen presentation
and subsequent CD4+ T cell activation (Bonacina et al., 2018), and APOE has been shown to
suppress T cell profileration (Laskowitz et al., 2000).
In melanoma, APOE suppresses primary and metastatic progression. Melanoma cells with
enhanced metastatic capacity upregulate a set of microRNAs that collectively repress the
expression of the Apoe gene (Pencheva et al., 2012). Mechanistically, APOE suppresses
melanoma invasion by binding to the LRP1 receptor on cancer cells. In addition to this tumor-
autonomous role, APOE suppresses endothelial recruitment by binding to LRP8 on endothelial
cells (Pencheva et al., 2012). Consistent with the suppressive role of extracellular APOE,
genetic inactivation of Apoe in the stroma also promotes melanoma progression. Interestingly,
both cancer- and stroma-derived APOE participate in the suppression of melanoma metastasis,
while the contribution of tumoral APOE to suppression of primary tumor growth seems negligible
(Pencheva et al., 2014). In addition to its impact on melanoma invasion and angiogenesis,
APOE also promotes anti-melanoma immunity by depleting MDSCs via its binding to the LRP8
receptor (Tavazoie et al., 2018). Of note, APOE may also impact outcome of other cancer types,
since Apoe-deficient mice exhibit increased progression of breast and ovarian cancer (Alikhani
et al., 2013; Lai et al., 2018).
Importantly, the anti-tumor capacity of APOE can be exploited therapeutically. Liver-X-
receptors (LXR) are transcription factors that promote the expression of Apoe (Evans and
Mangelsdorf, 2014), and pharmacologic activation of LXRs suppresses melanoma progression
through the transcriptional activation of Apoe (Pencheva et al., 2014).
1.5 Germline variants of APOE
In humans, there are three prevalent variants of APOE that differ from one another in just one
or two amino acids at positions 112 and 158 (Utermann et al., 1977; Weisgraber et al., 1981;
Utermann et al., 1984). The APOE2 variant has cysteines at both positions, the APOE3 variant
has a cysteine at the 112 and an arginine at the 158 position, and APOE4 has arginines at both
positions (Figure 1.2). These subtle sequence differences have major implications, since they
impact the tertiary structure of APOE and thereby modulate the binding affinity to its receptors
(Chen et al., 2011; Weisgraber et al., 1982; Kowal et al., 1990; Xian et al., 2018). Notably,
the two APOE-defining SNPs seem in almost perfect linkage disequilibrium, since the APOE1
genotype with the combination of an arginine at position 112 and a cysteine at position 158 has
been described in only four individuals to date (Belloy et al., 2019).
The worldwide distribution of APOE genotype varies substantially, with the APOE3 variant
being the most common in all human populations (Corbo and Scacchi, 1999). In Western
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populations, the allelic frequencies of APOE2 and APOE4 are approximately 8 % and 14 %,
respectively, rendering approximately 40 % of the Western population carriers of either the
APOE2 or APOE4 allele (Farrer et al., 1997). The allelic variation of APOE only exists in
humans. Evolutionarily, the APOE4 variant is considered the ancestral human allele (Hanlon
and Rubinsztein, 1995). However, while the sequence of primate and rodent APOE is most
similar to human APOE4, the tertiary struture and resulting function of APOE in these species
resembles APOE3 more closely (Raffai et al., 2001; McIntosh et al., 2012).
Germline variation of APOE has major pathophysiological implications. The APOE4 variant
is the biggest monogenetic risk for Alzheimer’s disease, while the APOE2 variant is protective
(Strittmatter et al., 1993; Corder et al., 1994). The risk for Alzheimer’s disease increases by
approximately 2- to 4-fold with one copy of APOE4, and by approximately 8- to 12-fold with
two copies (Farrer et al., 1997). In addition to their role in Alzheimer’s disease, APOE variants
modulate other inflammation-associated pathologies, including atherosclerosis, in which a
similar association between APOE-genotype and risk is seen (APOE4 > APOE3 > APOE2)
(Mahley, 2016; Bennet et al., 2007; Xu et al., 2016). APOE genotype is also one of the most
robust predictors of longevity, with APOE4 and APOE2 carriers exhibiting the shortest and
longest lifespans, respectively (Deelen et al., 2019).
Despite these firmly established epidemiologic associations and more than 10,000 studies
published on the association between APOE and Alzheimer’s disease, the mechanisms through
which APOE affects these outcomes remain incompletely understood. Indeed, in Alzheimer’s
disease, it is still debated whether the pathophysiological impact of APOE4 represents a gain or
loss of function (Belloy et al., 2019). However, mice in which the endogenous murine Apoe locus
is replaced with one of the three human APOE variants allow for the mechanistic dissection
of the action of APOE genotype, and their use has confirmed the causal role of APOE in the
aforementioned pathologies (Sullivan et al., 1997, 1998; Knouff et al., 1999).
Although an understanding of the molecular mechanism of APOE on these disease is lacking,
APOE variants haven been shown to modulate specific organismal processes. Most importantly,
given the role of APOE in modulating immune responses (see 1.4), it is not surprising that
variants of APOE differentially impact immunity. Carriers of the APOE4 genotype exhibit
increased cytokine secretion relative to APOE3 homozygotes (Gale et al., 2014) and altered
microglial phenotype (Krasemann et al., 2017; Shi et al., 2017). Additionally, APOE4 carriers
show expansion of CD4+ effector memory T cells and enhanced MHC-II mediated antigen
presentation (Bonacina et al., 2018). Consistently, human APOE4 targeted-replacement mice
show enhanced pro-inflammatory cytokine expression in microglia and macrophages upon LPS
exposure (Vitek et al., 2009; Ophir et al., 2005).
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Figure 1.2. APOE variants. Representation of APOE3 according to structural
analyses by Chen and colleagues (Chen et al., 2011). There are three prevalent
variants of APOE, which differ from one another in the presence of either cysteine or
arginine residues in positions 112 and 158, as indicated above.
1.6 Overview and biological significance
As outlined above, APOE suppresses melanoma progression. Given the existence of three
highly prevalent variants of APOE, this thesis investigates the hypothesis that APOE variants
differentially modulate melanoma progression and outcome. Despite the established patho-
physiological impact of APOE variants on several inflammation-related disease and their high
prevalence, the association between APOE germline status and cancer outcome has remained
inconclusive (Kulminski et al., 2014; Anand et al., 2014). To address this, we here analyze
melanoma progression in genetic mouse models expressing human APOE germline variants
and melanoma clinical trials to show that the APOE4 variant confers enhanced melanoma
outcome. In contrast, the APOE2 variant confers detrimental outcome. These differences
were due to differential anti-melanoma immune activation, and APOE4 carriers showed en-
hanced immunotherapy outcome, indicating a potential role of APOE germline status in guiding
melanoma therapy. Our findings show that the pathological impact of APOE variants is reversed
in melanoma in comparison to Alzheimer’s disease. More generally, APOE variants represent
the first example of highly common germline variants that modulate the outcome of a common
cancer type rather than its incidence.
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2 APOE germline variants modulate progression of
melanoma in-vivo
Previous studies from the Tavazoie laboratory showed that Apolipoprotein E (APOE) suppresses
melanoma progression (Pencheva et al., 2012, 2014). In humans there are three highly
prevalent variants of APOE that differ from one another in one or two amino acids. This chapter
explores the hypothesis that these variants differentially impact progression of melanoma.
To this end, progression of several independent melanoma models was assessed in mice
expressing distinct human APOE variants.
2.1 Human APOE germline variants modulate progression of murine
YUMM1.7 melanoma in-vivo
To assess whether APOE genotype modulates melanoma progression, we injected syngeneic
mouse YUMM1.7 melanoma cells into mice in which the endogenous mouse Apoe locus was
replaced with one of the human APOE variants, resulting in human APOE targeted replacement
(knock-in) mice (Knouff et al., 1999; Sullivan et al., 1997, 1998). The YUMM1.7 cell line was
originally derived from a genetically induced BrafV600E;Pten-/-;Cdkn2-/- tumor (Dankort et al.,
2009). Consistent with a causal impact of APOE genotype on melanoma progression, tumors
grew significantly faster in mice with the APOE2 genotype relative to APOE4 mice (Figure 2.1).
Tumor growth in APOE3 mice was intermediate between APOE2 and APOE4 mice, but the
differences between tumors in APOE3 mice and the other two genotypes were not significant.
We therefore decided to focus on assessing tumor growth in APOE2 versus APOE4 mice for
most subsequent experiments.
2.2 Human APOE germline variants modulate progression of murine
YUMM3.3 and YUMMER1.7 melanomas in-vivo
To assess whether the impact of APOE germline status on melanoma progression was true
across different models of melanoma, we next engrafted APOE-knock-in mice with cells from
the independent YUMM3.3 melanoma model, which was originally derived from a genetically
induced BrafV600E;Cdkn2-/- tumor (Meeth et al., 2016). Consistent with our observations in the
YUMM1.7 model, YUMM3.3 tumors progressed significantly faster in APOE2 relative to APOE4
mice (Figure 2.2a). Similarly, we observed faster tumor growth in APOE2 relative to APOE4
mice using the YUMMER1.7 melanoma model, a more immunogenic derivative of the YUMM1.7
model (Wang et al., 2017) (Figure 2.2b). These data indicate that APOE genotype impacts
melanoma progression across several syngeneic murine melanoma models.
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Figure 2.1. Stromal APOE genotype modulates progression of murine
YUMM1.7 melanoma. Growth of syngeneic mouse YUMM1.7 tumors in human
APOE targeted replacement mice (n = 11 per group, two-tailed t-test; representative
of two independent experiments). Images correspond to representative tumors on day
26 after injection (scale bar, 3 mm).
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Figure 2.2. Stromal APOE genotype modulates progression of YUMM3.3 and
YUMMER1.7 melanomas. (a, b) Growth of YUMM3.3 (a) and YUMMER1.7 (b)
tumors engrafted in APOE2 and APOE4 targeted replacement mice (n = 13 per group
for (a) and ≥ 11 for (b); two-tailed t-tests; each representative of two independent
experiments).
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Figure 2.3. Human APOE germline variants modulate progression in a geneti-
cally induced melanoma model. (a) Experimental approach to assess the impact
of human APOE alleles on genetically induced mouse melanoma progression. (b)
Melanoma burden of mice described in (a) on day 35 after induction (P = 0.01, one-
tailed Mann-Whitney test). Images of representative skins are shown on the right.
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2.3 Human APOE germline variants modulate progression of
genetically induced syngeneic melanomas in-vivo
The APOE3 and APOE4 variants are the most prevalent germline variants of APOE, prompting
us to assess more thoroughly whether these genotypes differentially impact melanoma progres-
sion. We reasoned that a genetically induced mouse model of melanoma might provide more
resolution than a transplanble model to detect a potential difference in tumor progression. To
this end, we crossed APOE3 and APOE4 knock-in mice with the BrafV600E;Pten-/- mouse model,
in which melanocyte-specific expression of Cre can be induced through the administration of
Tamoxifen, resulting in the deletion of the tumor suppressor Pten and subsequent formation
of melanomas (Figure 2.3a) (Dankort et al., 2009). Mice with the APOE3 genotype showed
significantly increased melanoma burden on day 35 after induction in comparison with APOE4
mice (Figure 2.3b), consistent with APOE genotype significantly impacting progression in this
genetically induced model.
2.4 Human APOE germline variants modulate metastatic progression of
murine melanoma
To assess whether APOE germline variants also modulate progression of melanoma metastasis,
we used the syngeneic murine B16F10 melanoma model, which readily metastasizes to th lung
upon tail vein injection (Fidler, 1975). We observed that expression of Apoe was significantly
higher in B16F10 cells relative to YUMM1.7 cells (Figure 2.4a). To limit the contribution of
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murine APOE to total APOE levels in-vivo, we decided to use previously described B16F10-
shApoe cells, in which expression of Apoe is silenced using RNA-interference (Pencheva et al.,
2012). Consistent with our findings in the primary tumor models, metastatic progression of
B16F10 melanomas was faster in APOE2 mice relative to APOE4 mice (Figure 2.4b), indicating
that APOE genotype also modulates metastatic progression of melanoma.
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Figure 2.4. Human APOE variants modulate metastatic progression of murine
melanoma. (a) Relative expression of murine Apoe as determined by qRT-PCR in
B16F10 cells expressing shCtrl and shApoe hairpins and in YUMM1.7 cells. (b)
Bioluminescence imaging of metastatic progression of murine melanoma B16F10-TR-
shApoe cells intravenously injected into APOE knock-in mice (n = 10 per group; one-
tailed Mann-Whitney test; representative of two independent experiments). Images
correspond to representative mice on day 24 after injection.
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3 APOE germline variants modulate the immune
microenvironment in melanoma
APOE exerts pleiotropic functions in metabolism and immunity (Mahley, 2016; Shi and Holtzman,
2018). In cancer, APOE suppressess progression by inhibiting cancer cell invasion and
angiogenesis (Pencheva et al., 2012). It also promotes anti-tumor immunity by depleting
immunosuppressive myeloid-derived suppressor cells (Tavazoie et al., 2018). This chapter
assesses the mechanism through which different alleles of APOE impact melanoma progression.
Using flow cytometry, single cell RNA-sequencing and selective depletion experiments, we show
that APOE genotype modulates melanoma progression through the modulation of anti-tumor
immunity.
3.1 The melanoma microenvironment in APOE4 mice exhibits an
anti-tumor immune phenotype
To assess whether APOE genotype affects the melanoma immune microenvironment, we
performed flow cytometry on dissociated YUMM1.7 melanomas hosted by APOE2 and APOE4
mice (gating strategy depicted in Figure 3.1). Remarkably, APOE4 mice exhibited increased
recruitment of leukocytes into the tumor (Figure 3.2a).
Consistent with a shift towards an anti-tumor immune phenotype, the relative abundance
of immune cells known to exert pro-tumor functions such as Ly6G+ granulocytic MDCSs
and tumor-associated macrophages was diminished in the APOE4 microenvironment (Figure
3.2b), while anti-tumor effector cells, such as natural killer cells (NK cells) and T cells, were
expanded (Figure 3.2c). Consistent with increased activation in APOE4 mice, these effector
cell populations also expressed higher levels of effector molecules, such as Granzyme B and
Interferon-‚ (Figure 3.2d-f).
To validate these flow cytometry results, we stained sections of YUMM1.7 tumors hosted by
APOE2 and APOE4 mice for CD8+ T cells using immunofluorescence. Consistent with the flow
cytometry results, tumors hosted by APOE4 mice exhibited increased infiltration of CD8+ T
cells (Figure 3.3).
3.2 Single-cell RNA-sequencing reveals profound modulation of the
melanoma immune microenvironment by APOE genotype
The tumor immune microenvironment is highly complex (Binnewies et al., 2018). Flow cytometry
is limited by the number of parameters that can be simultaneously assessed, and particularly the
assessment of the functional status of myeloid cells in the tumor microenvironment is challenging
by flow cytometry (Broz et al., 2014; Binnewies et al., 2019). To more comprehensively
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profile the immune microenvironment, we performed single cell RNA-sequencing on CD45+
leukocytes isolated from YUMM1.7 tumors in APOE2 and APOE4 mice. We profiled 10,050
CD45+ cells and clustered them into 26 groups using differential gene expression analysis and
cross-referencing top differentially expressed transcripts with the immunological genome project
(Yoshida et al., 2019) (Figure 3.4). Single cell RNA-sequencing revealed profound heterogeneity
in the tumor immune microenvironment, allowing us to capture small cell populations, such as
skin-resident macrophages and basophils.
Consistent with our flow cytometry results, the immune microenvironment in APOE4 mice
showed a pronounced shift towards an anti-tumor phenotype, with expansion of anti-tumor effec-
tor cells, such as NK and T cells, and depletion of tumor-promoting cells, such as macrophages
(Figure 3.5a). Single-cell RNA-sequencing also validated enhanced activation of anti-tumor
effector cells in APOE4 mice (Figure 3.5b-d).
To assess the functional status of different clusters in the tumor immune microenvironment
more globally, we performed pathway analysis on the gene expression profiles of clusters in
APOE4 versus APOE2 mice. Remarkably, many clusters in APOE4 mice showed enrichment of
pathways implicated in anti-tumor immunity, such as Interferon-signaling and allograft rejection
(Figure 3.6). Conversely, genes upregulated in clusters of APOE2 mice showed enrichment
for pathways implicated in tumor progression, such as angiogenesis. Overall, single cell RNA-
sequencing of CD45+ tumor-infiltrating leukocytes showed a shift in APOE4 relative to APOE2
mice in terms of both abundance and activation status towards an anti-tumor phenotype.
3.3 APOE receptors are differentially expressed in tumor-infiltrating
leukocytes between APOE2 and APOE4 mice
Several receptors are known to bind APOE, many of which bind APOE variants with different
affinites (Holtzman et al., 2012). To assess whether APOE genotype associated with differential
19
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expression of such APOE receptors, we assessed their expression in the immune microenvi-
ronment. Analzying all cells together, we observed upregulation of Ldlr and downregulation of
Lrp1 and Trem2 in leukocytes of APOE4 mice (Figure 3.7a). Expression of these receptors
was mostly limited to myeloid cells (Figure 3.7b), and several individual clusters showed sig-
nificantly differential expression between APOE4 and APOE2 mice (Figure 3.7c). These data
suggest that particularly Lrp1 and Trem2 may be promising candidates for further study of the
mechanistic basis of modulation of anti-tumor immunity by APOE genotype.
3.4 The impact of APOE genotype on melanoma progression depends
on adaptive T cell immunity
We next asked whether the impact of APOE genotype on melanoma progression was mediated
by modulating anti-tumor immunity. To this end, we assessed YUMM1.7 melanoma progression
in APOE2 versus APOE4 mice and depleted CD4+ and CD8+ T cells in two cohorts of mice.
Weekly administration of anti-CD4+ and anti-CD8+ antibodies resulted in efficient depletion of
T cells, as evidenced by flow cytometry of samples from tumors, lymph nodes, and spleens
(Figure 3.8a). Remarkably, while melanomas expectedly progressed faster in APOE2 than in
APOE4 mice receiving PBS injections, this effect was completely abrogated in mice depleted
for T cells (Figure 3.8b). These data suggest that the adaptive immune system is a critical
mediator of the impact of APOE genotype on melanoma progression.
3.5 Distinct APOE genotypes in the hematopoietic cell compartment are
sufficient to differentially impact melanoma progression
Next to the liver, hematopoietic cells are a major source of APOE in the body (Holtzman et al.,
2012). We therefore sought to assess whether distinct APOE genotypes in the hematopoietic
compartment would be sufficient to differentially impact melanoma progression. To this end, we
transplanted hematopoietic stem cells from APOE2 or APOE4 donors into lethally irradiated
C57Bl6j wildtype mice. Upon reconstitution, we injected these mice with YUMM1.7 melanomas.
Consistent with our findings in APOE2 versus APOE4 mice, YUMM1.7 melanomas progressed
faster in mice transplanted with APOE2 hematopoietic stem cells than in APOE4 transplanted
mice (Figure 3.9). These data implicate hematopoietic APOE genotype as a modulator of
melanoma progression.
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4 APOE germline variants associate with outcome in
human melanoma
The previous chapters have established that APOE germline variants causally modulate
melanoma progression by modulating anti-melanoma immunity. This chapter explores whether
these results translate to human patients with melanoma. To this end, we analyzed large
studies of melanoma patients and correlated APOE genotype with melanoma outcome.
4.1 APOE germline variants associate with survival in melanoma
patients of the TCGA study
To assess the association of APOE germline genotype and and melanoma outcome in humans,
we analyzed the melanoma study of The Cancer Genome Atlas (TCGA) (The Cancer Genome
Atlas Network, 2015) (Figure 4.1a). Using normal tissue whole exome sequencing data,
sufficient read depth was available to genotype 460 out of 470 patients of the study (Figure
4.1b). We focused on patients at increased risk of relapse and melanoma-associated death
(stage II/III at diagnosis).
We first compared the distribution of APOE genotypes in melanoma patients to the general
population. In comparison to the study with healthy participants of the Atherosclerosis Risk in
Whole exome sequencing
normal tissue samples
of the TCGA-SKCM study
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Figure 4.1. Overview of the analysis of melanoma patients in the TCGA study.
(a) Schematic of approach to analyze melanoma patients in the TCGA study. (b)
Read depth for the two APOE genotype-determining genomic loci in normal tissue
whole exome sequencing data of melanoma patients.
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Figure 4.2. Distribution of APOE carrier status and bi-allelic genotype in stage
II/III melanoma patients of the TCGA study. (a-b) Proportion of APOE2 and APOE4
carrier status (a) and bi-allelic genotype (b) in the Atherosclerosis Risk in Communities
study (ARIC) and in patients with stage II/III melanoma in the TCGA-SKCM study (P
= 0.0017 and 0.0066, respectively; ffl2 test).
Communities study (ARIC), which is similar in age and ethnic composition (Blair et al., 2005),
neither the APOE2 nor the APOE4 was enriched in melanoma patients (Figure 4.2), indicating
that neither of these variants predisposed for increased melanoma incidence.
We next assessed APOE genotype in matched tumor samples of the same patients. The
distribution of APOE genotypes was comparable between normal and tumor tissue samples
(Figure 4.3a), and we identified the same carrier status in sample pairs of 95.6 % of patients
with available results (94.2 % of all samples; Figure 4.3b). These congruent findings between
normal tissue and tumor samples suggest that our genotyping approach was robust and that
loss of heterozygosity events in the tumor were rare.
We then assessed the association between APOE genotype and survival outcome. Re-
markably, APOE genotype was significantly associated with survival in stage II/III melanoma
patients, whereby patients carrying at least one APOE2 or APOE4 allele showed the shortest
and longest survival, respectively (median survival of 2.4, 5.2, and 10.1 years in APOE2 carriers,
APOE3 homozygotes, and APOE4 carriers, respectively; P = 0.0038, log-rank test; Figure
4.4a). APOE2 carriers exhibited an increased hazard ratio versus APOE3 homozygotes (HR =
2.08, P = 0.01) and versus APOE4 carriers (HR = 3.69, P < 0.001) in this data, as revealed by
Cox proportional hazard regression analysis (Figure 4.4b).
To assess variables that may act as potential confounders we investigated the distribution
of major clinical and tumoral characteristics in patients stratified by APOE genotype. We did
not detect significant differences between any of these variables (Figure 4.5). Consistently,
multivariate analysis revealed APOE genotype to remain significantly associated with survival
(Figure 4.6).
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Figure 4.3. APOE genotype in matched normal tissue and tumor samples of
stage II/III patients in the TCGA-SKCM study. (a) Proportion of APOE2 and APOE4
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Figure 4.5. Clinical characteristics of stage II/III patients in the TCGA-SKCM
study. (a) Sex proportions were not significantly different between APOE carrier
groups (P = 0.46, ffl2 test). (b) Age at diagnosis was not significantly different between
APOE carrier groups (P = 0.45, Kruskal-Wallis rank sum test). (b) Tumor stage at
diagnosis was not significantly different between APOE carrier groups (P = 0.4, ffl2
test). (d) Melanoma Clark level at diagnosis was not significantly different between
APOE carrier groups (P = 0.95, ffl2 test). (e) Breslow depth was not significantly
different between APOE carrier groups at diagnosis (P = 0.24, Kruskal-Wallis rank
sum test). (f) Proportion of molecular subtypes stratified by APOE carrier status in
the TCGA-SKCM study (P = 0.93, ffl2 test). (g) Proportion of APOE carrier status
across transcriptional clusters of the TCGA-SKCM study (P = 0.55, ffl2 test). Hinges
of boxplots represent the first and third quartiles, whiskers extend to the smallest
and largest value within 1.5 × interquartile ranges of the hinges and points represent
outliers.
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Figure 4.6. Univariate and multivariate survival analysis of stage II/III melanoma
patients of the TCGA study. (a) Univariate analysis of the impact of clinical and
molecular characteristics on survival of stage II/III melanoma patients (P values ac-
cording to univariate Cox proportional hazards model). (b) Multivariable analysis
of the impact of clinical and molecular characteristics with significant impact in uni-
variate analysis on survival of stage II/III melanoma patients (P values according to
multivariable Cox proportional hazards model).
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Figure 4.7. APOE genotype imputation in the MDACC melanoma GWAS. (a-b)
Distribution of APOE carrier status in the Atherosclerosis Risk in Communities study
(ARIC) and the MDACC melanoma study before (a) and after (b) imputation of APOE
genotype (P < 2.2×10−16 and < 1.821×10−11, respectively; ffl2 test).
4.2 APOE germline variants are associated with survival in high-risk
melanoma patients of an independent study
To validate these findings in an independent study, we analyzed a genome-wide association
study (GWAS) reporting on the outcome of melanoma patients (Amos et al., 2011). Array chips
often used in GWAS studies have been reported to not adequately genotype the APOE defining
loci (Radmanesh et al., 2014). Consistent with inadequate genotyping, we found no individual
of the large MDACC study to exhibit the minor allele at the rs429358 locus, prompting us to
impute genotype at this locus based on a previously validated approach (Radmanesh et al.,
2014) (Figure 4.7).
Consistent with the association of APOE genotype with survival in the TCGA study, APOE
genotype was associated with survival in patients at high risk of melanoma-associated death
in the MDACC study (Clark level 5), with APOE2 carriers surviving the shortest. In contrast,
APOE2 patients with early stage melanomas – and therefore low risk of melanoma-associated
death – trended towards better survival (Figure 4.8). These findings are consistent with the
established association of APOE2 with enhanced lifespan in the general population (Deelen
et al., 2019).
Notably, patients in the TCGA study exihibited features conferring higher risk for melanoma-
associated death, such as older age and more advanced Clark level (Figure 4.9a-c). These
factors are likely reasons underlying the overall better outcome in patients in the MDACC study
relative to the TCGA-SKCM study (Figure 4.9). When restricting the analysis of MDACC patients
to those at hightest risk for relapse and melanoma-associated death as defined by advanced
age and high Clark level, APOE genotype exhibited a similarly strong association with survival
outcome as in the TCGA study (Figure 4.9e). Therefore, the known impact of germline genetic
variants of APOE on survival was reversed in patients with advanced melanoma, who were at
increased risk for melanoma-associated death.
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Figure 4.8. Impact of APOE genotype on survival of melanoma patients in the
MDACC study. Survival of melanoma patients in the MDACC study stratified by local
melanoma stage and APOE genotype (log-rank tests).
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5 APOE germline variants modulate melanoma
outcome in the context of immunotherapy
As outlined in the introduction, immunotherapy has transformed the therapy of melanoma
patients (see 1.2.3). Our observations that APOE genotype impacts melanoma progression
and outcome described above were mainly focused on mice and humans that did not receive
immunotherapy. This chapter explores whether the association between APOE genotype and
melanoma outcome is also true in the context of checkpoint-inhibition immunotherapy. Using
mice and human studies, we found that APOE genotype also associates with outcome in mice
and humans receiving anti-PD1 checkpoint inhibition.
5.1 APOE germline variants modulate melanoma progression in the
context of PD1-checkpoint inhibition in-vivo
To assess whether APOE genotype also modulates progression and outcome of melanoma
in the context of anti-PD1 immunotherapy, we injected highly immunogenic YUMMER1.7
melanoma cells into APOE2 and APOE4 mice and treated these mice with anti-PD1 inhibition.
We used the YUMMER1.7 melanoma model because of its susceptibility to checkpoint inhibition
(Wang et al., 2017). A larger fraction of mice with the APOE4 genotype achieved a complete
remission with anti-PD1 inihibition relative to APOE2 mice, translating into significantly longer
survival in APOE4 versus APOE2 mice (Figure 5.1)
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Figure 5.1. APOE genotypes modulates melanoma progression in the context
of anti-PD1 immunotherapy. (a-b) Tumor growth (a) and survival (b) of human
APOE knock-in mice injected with YUMMER1.7 tumors and treated with anti-PD1
antibody (n = 26 per group; P = 0.022, two-tailed log-rank test; data pooled from two
independent experiments; CR = complete remission).
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5.2 APOE germline variants associate with survival in melanoma
patients receiving second-line immunotherapy
5.2.1 Analysis of the Roh et al. study
To assess whether the association of APOE genotype with outcome in melanoma in the
context of immunotherapy also applies to humans, we assessed a study of advanced-stage
melanoma patients that received anti-PD1 immunotherapy after failing or progressing on first-
line immunotherapy with anti-CTLA4 inhibition (Roh et al., 2017). The distribution of APOE
carrier status was not significantly different between this study and the healthy population in the
ARIC study (Blair et al., 2005) (Figure 5.2a). In analogy to our approach analyzing the TCGA
study, we also compared genotyping results from matched normal and tumor tissue samples.
Genotyping results were identical for 32 out of 34 patients (94 %), confirming our genotyping
approach to be robust and tumor loss of heterozygosity events to be rare (Figure 5.2b).
We next assessed clinical response and survival in patients that sequentially received both
anti-CTLA4 and anti-PD1 targeting therapy. While there was a trend towards a better response
in patients with the APOE4 genotype according to the RECIST criteria, this was not significant
(Figure 5.2c). Remarkably, however, APOE4 carriers showed the best survival outcomes, while
patients with at least one copy of the APOE2 variant survived the shortest (Figure 5.2d). These
data are consistent with our observations in the TCGA and MDACC studies, in which most
patients did not receive immunotherapy.
5.2.2 Validation in the Riaz et al. study
To validate these results, we analyzed the study by Riaz et al., in which patients received
anti-PD1 therapy either as first-line immunotherapy or after failing or progressing on anti-CTLA4
therapy (Riaz et al., 2017). Consistent with our findings in the Roh et al. study, in patients
receiving PD1-blockade after failing or progressing under anti-CTLA4 therapy, there was no
significant difference in the distribution of APOE carrier status (Figure 5.3a), but APOE4 and
APOE2 carriers surved the longest and shortest, respectively (Figure 5.3b). In patients receiving
upfront immunotherapy with PD1-inhibition, genotype distribution was also not significantly
different between melanoma patients and healthy individuals (Figure 5.4a). However, in contrast
to patients receiving second-line immunotherapy with anti-PD1, we did not observe a significant
association of APOE genotype and survival in these patients (Figure 5.4b). This may be due to
either the small sample size, or it may point to a context-specific impact of APOE genotype
on melanoma progression. Overall, our findings from both mouse models and human clinical
data show that APOE genotype impacts melanoma progression in the context of anti-PD1
immunotherapy.
5.3 APOE germline variants predict response to LXR-agonistic
immunotherapy
Activation of Liver-X-receptor (LXR) transcription factors has been shown to promote anti-tumor
immunity via transcriptional activation of APOE (Tavazoie et al., 2018). We reasoned that
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Figure 5.2. Analysis of the impact of APOE genotype on outcome of melanoma
patients receiving second-line immunotherapy with anti-PD1 in the Roh et al.
study. (a) Comparison of the distribution of APOE carrier status in patients of the
Roh et al. study with healthy individuals of the ARIC study (P = 0.3978, ffl2 test).
(b) Chord diagram of APOE carrier status as identified in paired normal and tumor
tissue samples of melanoma patients in the Roh et al. study. (c) Clinical response
to anti-PD1 therapy according to RECIST criteria in melanoma patients stratified by
APOE genotype (P = 0.171, asymptotic linear-by-linear association test). (d) Survival
of patients from (a-c) stratified by APOE genotype (log-rank test).
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Figure 5.3. Analysis of the imapct of APOE genotype on second-line
immunotherapy-treated melanoma patients from the Riaz et al. study. (a) Com-
parison of the distribution of APOE carrier status in melanoma patients receiving
second-line immunotherapy from the Riaz et al. study with healthy participants from
the ARIC study (P = 0.1744, ffl2 test). (b) Survival of patients from (a) stratified by
APOE carrier status (log-rank test).
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Figure 5.4. Association of APOE genotype with outcome in upfront anti-PD1
immunotherapy-treated melanoma patients. (a) Comparison of the distribution of
APOE carrier status in melanoma patients receiving first-line immunotherapy from
the Riaz et al. study with healthy participants from the ARIC study (P = 0.6829,
ffl2 test). (b) Survival of melanoma patients treated with anti-PD1 therapy with no
prior checkpoint therapy from the Riaz et al. study stratified by APOE carrier status
(log-rank test).
38
RGX-104 (LXR agonist)
a b
0 10 20 30 40
0
200
400
600
800
1000
Tu
m
or
vo
lu
m
e
(m
m
3 )
APOE2
Control
RGX-104 n.s.
0 10 20 30 40
APOE4
Control
RGX-104
****
DayDay
Co
ntr
ol
RG
X-
10
4
Co
ntr
ol
RG
X-
10
4
0
500
1000
1500
2000
2500
Tu
m
or
vo
lu
m
e
(m
m
3 )
n.s.
****
APOE2 APOE4
Figure 5.5. APOE genotype predicts response to LXR-agonistic immunother-
apy. (a) Effect of LXR-agonistic treatment on growth of YUMM1.7 tumors in human
APOE knock-in mice (n ≥ 10 per group, two-tailed t-test; representative of two in-
dependent experiments). (b) Individual tumor volume on day 29 post injection from
(a).
APOE genotype may associate with response to LXR-agonistic therapy. To test this, we treated
YUMM1.7 melanoma-bearing APOE2 and APOE4 mice with the synthetic LXR agonist RGX-
104 (Tavazoie et al., 2018). Remarkably, LXR agonistic treatment conferred robust anti-tumor
activity in mice with the APOE4 genotype, while efficacy was completely blunted in APOE2
mice (Figure 5.5). These data indicate that APOE genotype may serve as a biomarker to
predict response to LXR-agonistic therapy.
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6 Discussion
Germline variants of the APOE gene have major pathophysiological implications. The APOE4
variant, present in approximately 25 % of Western populations, is the biggest monogenetic
risk factor for Alzheimer’s disease, while APOE2 is protective. APOE variants also impact
cardiovascular disease. Despite their high prevalence and their impact on inflammation-
associated diseases, the role of APOE variants in modulating cancer outcome has been
unclear.
APOE was previously shown to suppress melanoma progression and metastasis. Therefore,
this thesis investigated the hypothesis that common APOE variants differentially modulate
melanoma outcome. Using genetic mouse models and large human melanoma trial data, we
show that, in a reversal of their impact on neurodegeneration and cardiovascular disease, the
APOE4 and APOE2 variants confer favorable and poor outcomes in melanoma, respectively,
by impacting anti-tumor immunity.
6.1 Overview of major findings
To elucidate whether APOE germline variants modulate melanoma progression, we assessed
the growth of three transplantable melanoma models in mice expressing human APOE variants.
Across these models, APOE4 mice showed slower melanoma progression than APOE2 mice.
Consistent with these primary tumor data, progression of melanoma metastasis was slower
in APOE4 mice relative to APOE2 mice. Additionally, melanoma burden in a genetically
inducible model was lower in APOE4 mice relative to APOE3 mice. Importantly, these models
allowed us to conclude that the impact of APOE genotype on melanoma progression is causal.
Previous work showed that stroma-derived APOE is the main modulator of melanoma primary
tumor progression (Pencheva et al., 2014). It is consistent with these previous results that we
detected significant effects of stromal APOE genotype on melanoma progression when using
transplantable melanoma models, in which APOE genotype is different only in the stroma and
not in the tumor compartment.
To assess how APOE variants impact melanoma progression, we characterized the tumor im-
mune microenvironment in APOE variant mice. Flow cytometry and single cell RNA-sequencing
approaches showed enhanced anti-tumor immune activation in APOE4 relative to APOE2 mice.
Consistent with an essential role of the immune system in mediating the impact of APOE
variant status on melanoma progression, depletion of T cells completely abrogated this impact.
Additionally, by transplanting hematopoietic stem cells from APOE2 and APOE4 hosts, we
showed that hematopoietic cell APOE genotype is sufficient to differentially modulate melanoma
progression. Enhanced immune activation in APOE4 mice in the context of anti-tumor immunity
described in this thesis is consistent with the pro-inflammatory cytokine profile of APOE4 versus
APOE3 microglia and macrophages (Vitek et al., 2009; Ophir et al., 2005; Shi et al., 2017) and
enhanced cytokine secretion in human APOE4 carriers (Gale et al., 2014).
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One important question that arose from these in-vivo data was whether this effect could
also be observed in humans. To investigate this, we assessed APOE genotype in normal
tissue whole-exome sequencing data from stage II/III melanoma patients of the TCGA-SKCM
study (The Cancer Genome Atlas Network, 2015). Remarkably, APOE genotype significantly
associated with survival. Consistent with our observations in human APOE knock-in mice,
patients that carried the APOE2 allele showed significantly worse survival than APOE3 ho-
mozygotes and APOE4 carriers. As alluded to above (see 1.4), it was previously established
that APOE4 and APOE2 correlate with reduced and enhanced longevity, respectively (Belloy
et al., 2019). It is therefore surprising that we detected enhanced survival in APOE4 carriers,
since the impact of APOE genotype on longevity would be expected to counter the reversed
impact on melanoma outcome. It is likely that our ability to detect this reversal on survival in
melanoma patients is due to the pronounced risk of melanoma-associated death in the high-risk
group of TCGA-SKCM patients (The Cancer Genome Atlas Network, 2015). To validate these
results, we analyzed data from a genome-wide association study in melanoma patients (Amos
et al., 2011). Consistent with our observations in the TCGA-SKCM study, amongst patients at
high risk of melanoma-associated death (Clark level V), APOE2 carriership associated with
detrimental survival outcome. In contrast, survival outcomes trended worse for APOE4 carriers
in patients with lower-risk melanomas, consistent with the previously established impact of
APOE genotype on longevity.
We also sought to assess the impact of APOE genotype on melanoma outcome in the context
of immunotherapy. APOE4 melanoma-bearing mice survived longer than APOE2 mice upon
PD1-checkpoint blockade, and the analysis of two independent studies confirmed favorable
survival in APOE4 relative to APOE2 carriers in patients receiving PD1-blockade after failing
or progressing under CTLA4-blockade. These results are consistent with our observations in
the absence of immunotherapy and indicate that APOE genotype also modulates melanoma
outcome in the context of immunotherapy. As will be discussed in more detail below, these
results have major potential clinical implications, since immunotherapy has become the mainstay
of advanced melanoma therapy. Finally, previous work from our laboratory has shown that
activation of LXRs confers anti-melanoma efficacy through the transcriptional activation of
APOE (Tavazoie et al., 2018). We therefore assessed whether APOE genotype predicts for
response to LXR agonism. While APOE4 mice derived robust treatment benefit from LXR
agonism, there was no effect in APOE2 mice. These data indicate that APOE genotype may
be a useful biomarker for LXR agonism in melanoma patients.
6.2 Biological and clinical relevance
Our findings of an impact of highly prevalent APOE germline variants on melanoma progression
are novel in multiple regards. They constitute the first example of highly common germline
variants that causally modulate cancer outcome. Of note, our observations are different from
the established role of germline mutations in tumor suppressor genes that modulate cancer
incidence, rather than cancer outcome, such as BRCA1/2 (Miki et al., 1994; Wooster et al.,
1995). Additionally, in contrast to APOE variants, such previously described mutations play
a role in the tumor compartment rather than in the stroma. One previous study revealed that
polymorphisms in the FCGR3A gene are associated with the outcome of ipilimumab treatment
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in melanoma patients (Arce Vargas et al., 2018). However, in contrast to our findings presented
here, this association was merely correlative.
While immunotherapy has transformed the treatment of melanoma, it is important to identify
biomarkers that predict for (i) whether patients are at high risk of relapse and melanoma-
associated death and for (ii) treatment outcome (Larkin et al., 2019). Several biomarkers have
previously been identified, such as tumor mutational burden and PD-L1 expression, but these
are not robust enough for individual patient stratification (see 1.3.1). Therefore, it is a major
unmet need to characterize biomarkers that identify patients that are most likely to benefit from
therapeutic intervention. Our findings constitute the first example of common germline variants
having a major causal impact on anti-tumor immunity, and they show that variants within the
same gene can either promote or blunt immune responses. Importantly, APOE genotype
correlated with outcome of melanoma patients also in the context of immunotherapy, indicating
that APOE genotype is a promising candidate for a biomarker to both predict risk for adverse
outcome in melanoma patients as well as to predict for response to therapy. Prospective clinical
trials will need to validate the potential role of APOE as a biomarker.
Another clinical implication concerns Alzheimer’s disease, for which recent efforts have
assessed the feasibility of converting the APOE4 variant into APOE2 to mitigate APOE4’s
detrimental impact (Abudayyeh et al., 2019). Our results call for careful investigation into the
potential harmful effects of such efforts, such as deleterious effects on cancer outcomes.
6.3 Perspectives
Our findings raise several important questions that will need to be addressed in the future. The
most important points will be discussed below.
6.3.1 The molecular link between APOE genotype and anti-tumor immunity
In this work, we show that APOE variants modulate melanoma outcome by impacting anti-tumor
immunity. Moving forward, it will be important to determine the molecular mechanisms that
mediate this impact. Previous work from the Tavazoie laboratory showed that APOE promotes
anti-tumor immunity by depleting immunosuppressive MDSCs via binding to the APOE receptor
LRP8 (Tavazoie et al., 2018). It is conceivable that different APOE variants exhibit differential
capacities to deplete MDSCs via differential activation of LRP8 signaling. For some APOE
receptors, such as LDLR and LRP1, different binding affinites to distinct APOE variants have
been shown, whereby APOE4 and APOE2 exhibit the highest and lowest binding affinities,
respectively (Weisgraber et al., 1982; Kowal et al., 1990). This binding affinity pattern also
seems to apply to LRP8, the receptor involved in MDSC depletion, for which APOE2 exhibits the
lowest binding affinity (Xian et al., 2018). To complicate matters, the differential impact of APOE
variants on receptor signaling is not limited to different binding affinities: in the case of LRP8,
pH-dependent conformational changes of APOE4 lead to an endosomal trafficking defect,
which modulates receptor surface expression and is likely to exert secondary effects (Xian
et al., 2018). To assess whether the APOE/LRP8 axis in MDSCs accounts for the differential
impact of APOE variants on anti-melanoma immunity, it will be necessary to perform in-vitro
experiments exposing MDSCs to recombinant APOE variants and assess cell viability. In
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addition, to conclude whether myeloid LRP8 mediates the in-vivo impact of APOE variants,
tumor growth experiments will need to be performed with conditional deletion of LRP8 on
myeloid cells in the APOE2 and APOE4 contexts.
Of note, APOE is known to bind to several other receptors of the LDLR family as well as
to TREM2 in addition to LRP8 (see 1.4). Our single cell RNA-sequencing data allowed us to
assess the expression of APOE receptors in immune subsets with the hypothesis that differential
activation of APOE receptors may lead to transcriptional feedback. Expression differences of
the LRP1 and TREM2 receptors were most pronounced between APOE2 and APOE4 immune
cells, indicating the potential participation of these receptors in mediating the effect of APOE
variants. Of note, it has been previously shown that profiling of granulocytic MDSCs by single
cell RNA-sequencing is not optimal (Martin et al., 2019). Therefore, the expression of receptors
in granulocytic MDSCs should be assessed using orthogonal approaches. Interestingly, myeloid
LRP1 has previously been implicated in anti-tumor immunity (Staudt et al., 2013; Sedlacek
et al., 2019). In addition, TREM2 variants are known to associate with Alzheimer’s risk and
modulate microglial immune phenotypes (Krasemann et al., 2017; Shi and Holtzman, 2018).
These previous observations suggest a potential role of APOE receptors other than LRP8 in
mediating the impact of APOE variants on melanoma progression and render it necessary to
perform the experiments proposed above for LRP8 for other APOE receptors as well.
It is conceivable that systemic effects of distinct APOE genotypes also participate in modulat-
ing anti-tumor immunity in addition to direct APOE/APOE-receptor signaling on immune cells.
One major systemic factor that is impacted by APOE gentoype is cholesterol homeostasis
(Bennet et al., 2007). Hypercholesterolemia is known to modulate immunity, as exemplified by
its suppression of antiviral T cell cytotoxicity in the context of viral liver infection (Ludewig et al.,
2001). However, immune modulation of APOE was maintained in the context of altering APOE
status only in the hematopoietic system, which allows to decouple the role of hematopoietic
APOE from hypercholesterolemia (Bonacina et al., 2018). Additionally, microglia from APOE3
and APOE4 mice showed differential cytokine secretion when cultured in-vitro (Vitek et al.,
2009). These findings indicate that APOE may impact immunity independent from its effect on
systemic cholesterol homeostasis.
An alternative hypothesis potentially explaining the impact of APOE on immunity is based on
its impact on the composition and turnover kinetics of cell membranes. Specifically, APOE has
been shown to modulate lipid rafts, which can act as scaffolds for the assembly of signaling
molecules. The APOE4 variant was shown to be less effective than APOE3 in inducing
cholesterol efflux from cells, thereby leading to cholesterol retention in the cell membrane and
prolonged signaling and immune activation (Gale et al., 2014; Bonacina et al., 2018).
It is important to note that, due to APOE’s pleiotropic actions and its binding to several
receptors, the determination of its precise mechanism of action in cancer is challenging. Indeed,
despite a quarter century of research, there is still no definitive conclusion for how APOE
variants modulate the risk of Alzheimer’s disease. This is best exemplified by the notion that it
remains unresolved whether the APOE4 variant constitutes a gain- or loss-of-function variant
(Belloy et al., 2019). Part of this complexity arises from the fact that the function of APOE is
context- and process-specific. For example, the APOE4 variant exhibits higher binding affinity
to the LDLR and LRP1 receptors, thereby acting in a gain-of-function manner compared to the
other variants (Weisgraber et al., 1982; Kowal et al., 1990). Additionally, APOE4 mice showed
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increased susceptibility to Tauopathies relative to Apoe-/- mice (Shi et al., 2017). In contrast,
however, its impact on cholesterol efflux is more akin to APOE deletion (Bonacina et al., 2018),
consistent with a loss-of-function. Regarding the impact of APOE genotype on anti-melanoma
immunity described in this work, previous work showed blunting of anti-tumor immunity in
Apoe-knockout mice, suggesting that the APOE4 variant exerts a gain-of-function impact. It
is likely that pleiotropic mechanisms account for the profound impact of APOE genotype on
anti-cancer immunity, and future work will need to systematically dissect these.
6.3.2 APOE variants in cancer beyond melanoma
In this work, given previous data showing that APOE suppresses melanoma progression
(Pencheva et al., 2012), we focused on assessing the impact of APOE variants on melanoma
outcome. It is an important question whether APOE genotype also impacts other cancer types.
The only published data approaching this question are epidemiologic studies. A meta-analysis
published in 2014 did not find an assocation between APOE genotype and cancer incidence,
but did not report on cancer outcome (Anand et al., 2014). Other epidemiologic studies suggest
a later onset of cancer in male APOE4 carriers (Kulminski et al., 2011, 2014). In addition,
APOE4 carriership correlated with better survival in female patients with chronic lymphocytic
leukemia (Weinberg et al., 2008).
Several reasons explain why the link between APOE genotype and melanoma progression
described here has not been readily established by previous studies. Most studies assessing
the impact of genetic variability on melanoma have focused on incidence, rather than survival
(Brown et al., 2008; Bishop et al., 2009; Barrett et al., 2011; Macgregor et al., 2011). Additionally,
most chip arrays used for cancer genome-wide association studies do not adequately capture
one of the APOE genotype-defining SNPs (Radmanesh et al., 2014). Lastly, the statistical
power of unbiased genome-wide studies is hampered by testing a vast number of hypotheses
in parallel. In contrast, our approach was guided by previous molecular biology findings from
our laboratory showing an impact of APOE on melanoma, thereby circumventing this problem.
In the absence of experimental data on the role of APOE variants in other cancer types,
it is useful to examine whether Apoe-deletion impacts progression of a given cancer type.
Interestingly, Apoe-/- mice exhibit faster progression of breast and ovarian cancers (Alikhani
et al., 2013; Lai et al., 2018). In contrast, repression of tumoral APOE blunted ovarian cancer
progression, hinting at potential differences between the roles of stromal and tumoral APOE
(Chen et al., 2005).
Overall, the sparse existing data support a potential role of APOE in modulating cancer types
beyond melanoma. A combination of assessing tumor progression in human APOE-transgenic
mice with the analysis of large-scale patient data will be required to address which cancer types
are impacted by APOE genotype.
6.3.3 Interaction with the impact of APOE genotype on melanoma progression
Previous studies have shown the effect of APOE genotype on certain phenotypes to be
modulated by other variables. In statistical terms, such variables are said to interact with
the impact of APOE genotype. Two of the best characterized interacting factors are ethnicity
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and sex. In Africans, the association of APOE4 with Alzheimer’s disease is only observable
in APOE4 homozygotes, while East-Asians seem more susceptible to the impact of APOE4
(Farrer et al., 1997). Ethnicity also seems to interact with the impact of APOE on cardiovascular
disease, longevity, and lobar hemmorhage (Bennet et al., 2007; Tzourio et al., 2008; Garatachea
et al., 2014; Sawyer et al., 2018). It is equally well established that sex interacts with the impact
of APOE genotype, since the association of APOE4 with Alzheimer’s disease is stronger
in women and in female mice (Payami et al., 1994; Farrer et al., 1997; Raber et al., 1998).
Interestingly, the sex-by-APOE interaction has also been found in macrophages cultured in-vitro
(Colton et al., 2005; Brown et al., 2007). Epidemiologic data suggest that a sex-by-APOE
interaction may also exist in cancer. The APOE4 variant associates with a delay in cancer
onset, but this association was only observed in males (Kulminski et al., 2011, 2014).
Further analysis of variables interacting with the impact of APOE genotype on cancer has the
potential to reveal its context-specificity. It may also offer cues to the mechanisms underlying
APOE ’s impact on cancer. To identify interacting factors, large-scale patient datasets should
be analyzed for interaction terms with APOE ’s impact on known associated traits, such as
melanoma outcome (reported in this thesis), and Alzheimer’s disease. Additionally, factors
that are known to interact with APOE in certain contexts should be assessed in targeted
experiments. For example, the sex-by-APOE interaction can be readily addressed in mouse
experiments. Of note, for experiments in this thesis, an impact of APOE genotype on melanoma
progression was observed in both female (YUMM3.3 and YUMMER1.7 experiments) and male
mice (YUMM1.7). However, a more systematic assessment of such potential interactions is
desirable.
6.3.4 The impact of APOE genotype on other immune-related contexts
As outlined above, APOE plays a major role in several pathophysiological contexts, such as
Alzheimer’s disease, cardiovascular disease, and cancer progression. A common element
in most of these processes is the impact of immunity. Indeed, as outlined in section 1.4,
Apoe-knockout mice exhibit immune dysfunction, and APOE-transgenic mice show altered
immune responses (Ophir et al., 2005; Vitek et al., 2009). In humans, APOE variants associate
with altered immune profiles (Gale et al., 2014; Bonacina et al., 2018). It has been discussed
before whether the differential impact of APOE variants on different immune processes may
have shaped its heterogeneous global distribution due to selective pressure (van Exel et al.,
2017). One hypothetical example would be pleiotropic antagonism, whereby APOE4 protects
from processes in which immune activation is beneficial, such as infection, while conferring
detrimental consequences in diseases promoted by inflammation, such as neurodegeneration.
However, it remains an unsolved question, to which degree APOE variants modulate the
outcome of common infectious diseases. This question should be approached using APOE-
transgenic mice. Additionally, APOE genotyping of infectious disease patients may provide
epidemiologic evidence supporting a potential association, as partially performed in the past
(van Exel et al., 2017).
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6.3.5 The germline genetic makeup in cancer progression
Our findings uncover an impact of highly prevalent germline variants on anti-cancer immunity.
Importantly, these findings suggest the possibility that other common polymorphisms at other
immune-related loci also participate in modulating disease outcome. A global assessment
of their role in outcome and therapy response is outstanding. This is in part due to the
sheer number of genetic variants, complicating their unbiased assessment because of power
limitations. Additionally, as outlined above, most studies analyzing germline variation in cancer
patients have so far focused on incidence rather than outcome (Brown et al., 2008; Bishop
et al., 2009; Barrett et al., 2011; Macgregor et al., 2011). The predicted use of routine germline
and tumor sequencing of cancer patients will provide opportunities to more globally define the
role of germline variation in cancer outcome. Determining how germline genetics shape an
individual patient’s outcome and response to therapy will be a key element of precision cancer
therapy and will help to optimize treatment efficacy while limiting unnecessary toxicity.
6.4 Conclusions
APOE was previously shown to suppress melanoma progression and metastasis. Because of
the presence of three highly prevalent APOE variants in humans, this thesis investigated the
hypothesis that APOE variants differentially modulate melanoma progression and outcome.
In a reversal of their impact on Alzheimer’s disease, we found that the APOE4 and APOE2
variants imparted favorable and poor outcomes in melanoma, respectively. These effects
were mediated by modulating anti-melanoma immunity, and the impact of APOE genotype on
melanoma outcome was also true in the context of immunotherapy. Our results show that highly
prevalent germline variants modulate the outcome and immune response in a common cancer
type. Additionally, they suggest that APOE genotype may be a valuable biomarker to predict for
adverse outcome and therapy response in melanoma patients.
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7 Material and methods
7.1 Animal studies
All animal experiments were conducted in accordance with a protocol approved by the Institu-
tional Animal Care and Use Committee at The Rockefeller University. Human APOE2 (strain
#1547), APOE3 (#1548), and APOE4 (#1549) targeted replacement (knock-in) mice were
obtained from Taconic Biosciences. C57BL6/J (#000664) and Tyr::CreER;BrafV600E/+;Ptenlox/lox
(#013590) mice were obtained from Jackson laboratories.
7.2 Tumor growth studies and treatments
To assess the impact of APOE genotype on the growth of syngeneic melanoma, 1 × 105
YUMM1.7 cells were subcutaneously injected into the flank of 6-10-weeks-old human APOE
targeted replacement mice. The sex of the mice for experiments with YUMM1.7, YUMM3.3 and
B16F10 cells was matched to the sex of the tumor cell line (males for YUMM1.7 and B16F10,
females for YUMM3.3). YUMMER1.7 cells were injected into female mice. Cells were injected
in a total volume of 100 µL, and YUMM1.7 cells were mixed 1:1 with growth factor reduced
Matrigel (356231, Corning) before injection. Tumor size was measured on the indicated days
using digital calipers and tumor volume was calculated as (small diameter)2× (large diameter)
/ 6. In experiments employing YUMMER1.7 cells, 5 × 105 cells resuspended in PBS were
injected subcutaneously into the flank.
To deplete T cells in-vivo, 400 µg of each anti-CD4 (BioXCell, clone GK1.5) and anti-CD8
(BioXCell, clone 53-6.7) antibodies were injected intraperitoneally on days 7, 14, and 21 post
tumor cell injection. Control mice received PBS injections on the same days. Efficient depletion
was verified by flow cytometry on day 27 post tumor injection. For LXR-agonistic treatment,
mice were administered chow supplemented with the synthetic LXR-agonist RGX-104 (Rgenix
(Tavazoie et al., 2018)) at 628.5 mg/kg chow (Research Diets, approximate target dose of 100
mg/kg body weight) starting on day 3 post injection. For anti-PD1 treatment, mice were injected
intraperitoneally with 250 µg and 125 µg of anti PD-1 antibody (BioXCell, clone RMP1-14) on
days 6 and 9 post tumor cell injection, respectively. Control mice received PBS injections on
the same days. For survival analysis in the YUMMER1.7 model, mice were euthanized when
the tumor volume exceeded 1000 mm3. Therapy responses were considered complete (CR,
complete response) when tumor volumes fell below 16 mm3 (lowest limit of detection).
7.3 Genetically initiated model of melanoma progression
Human APOE targeted replacement mice were crossed with Tyr::CreER;BrafV600E/+;Ptenlox/lox
mice. To induce melanoma, 6-7-weeks-old female mice were injected intraperitoneally with
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1 mg of Tamoxifen (T5648, Sigma-Aldrich) on three consecutive days. Tamoxifen solution
was prepared by dissolving Tamoxifen powder in 100 % ethanol at 50°C for five minutes and
subsequently diluted tenfold in peanut oil to yield a 10 mg/mL working solution. To assess
melanoma burden, dorsal skin samples stretching from ears to hips were harvested on day 35
after induction, depilated with commercial depilation cream (Nair), washed with water and fixed
in 4 % PFA. Skins were then scanned and the percentage of pigmented melanoma lesion area
was quantified using Cellprofiler v3.
7.4 Tail-vein metastasis assays
For tail-vein assays, B16F10-shApoe cells stably expressing a retroviral construct encoding
luciferase were used in order to assess cancer progression by bioluminescence imaging as
described previously (Pencheva et al., 2014). To assess whether APOE genotype impacts
metastatic progression, 1 × 105 cells were resuspended in 100 µL of PBS and injected into the
tail vein of 6-8-weeks-old male human APOE knock-in mice. Bioluminescence imaging was
performed approximately twice a week and the signal was normalized to the signal obtained on
day 0.
7.5 Mouse genotyping
Genotyping to distinguish between mouse and human APOE was performed using standard
PCR with independent reactions for mouse and human APOE (PCR product lengths of 200
bp and approximately 600 bp, respectively). In order to distinguish between human APOE
alleles, PCR-based restriction fragment length polymorphism genotyping was used (Hixson and
Vernier, 1990). In brief, a 244 bp fragment of APOE was amplified using standard PCR and
digested with HhaI (R0139S, New England Biolabs), and allele-specific products were resolved
on a 15% polyacrylamide gel. Primer sequences are listed in Table 7.1.
Table 7.1. Oligonucleotides for genotyping.
Target Sequence (5’ to 3’)
Tyr::CreER;BrafV600E/+;Ptenlox/lox mice
Cre transgene forward GCG GTC TGG CAG TAA AAA CTA TC
Cre transgene reverse GTG AAA CAG CAT TGC TGT CAC TT
Cre internal control forward CAC GTG GGC TCC AGC ATT
Cre internal control reverse TCA CCA GTC ATT TCT GCC TTT G
Braf forward TGA GTA TTT TTG TGG CAA CTG C
Braf reverse CTC TGC TGG GAA AGC GGC
Pten forward CAA GCA CTC TGC GAA CTG AG
Pten reverse AAG TTT TTG AAG GCA AGA TGC
Mouse versus human knock-in APOE
Common forward TAC CGG CTC AAC TAG GAA CCA T
Mouse Apoe reverse TTT AAT CGT CCT CCA TCC CTG C
Human APOE reverse GTT CCA TCT CAG TCC CAG TCTC
Continued . . .
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. . . continued
Target Sequence (5’ to 3’)
Human APOE allele restriction length polymorphism
Human APOE forward ACA GAA TTC GCC CCG GCC TGG TAC AC
Human APOE reverse TAA GCT TGG CAC GGC TGT CCA AGG A
7.6 Hematopoietic stem cell transplantation
Six to 7-weeks-old C57BL6/J mice were whole-body irradiated with 10.5 Gray (two doses of
525 rad each 3.5 hours apart). Six hours after the last dose of irradiation, 2-3 × 106 nucleated
bone marrow cells isolated from 6-8-weeks old APOE-knock-in mice (n = 5 per group) were
infused into recipient mice by retroorbital injection. Bone marrow chimeras were reconstituted
for 8 weeks before experimental use.
7.7 Cell lines
YUMM1.7 cells, originally derived from the genetic BrafV600E;Pten-/-;Cdkn2-/- mouse melanoma
model, as well as their more immunogenic derivative YUMMER1.7 were a kind gift from
Marcus Bosenberg (Meeth et al., 2016; Wang et al., 2017). YUMM3.3 BrafV600E;Cdkn2-/-
mouse melanoma, B16F10 mouse melanoma, and human umbilical vein endothelial cells
(HUVEC) were obtained from American Tissue Type Collection and cultured according to the
supplier’s conditions. B16F10 cells expressing luciferase (Ponomarev et al., 2004) and shRNA
targeting murine Apoe (shRNA clone TRCN0000011799; B16F10-TR-shApoe) were described
previously (Pencheva et al., 2014). MeWo melanoma cells were obtained from American Tissue
Type Collection, and their highly metastatic MeWo-LM2 subclone was described previously
(Pencheva et al., 2012). B16F10 and MeWo-LM2 cells were cultured in DMEM medium
with Pyruvate and Glutamine (11995, Gibco) supplemented with 10 % FBS (F4135, Sigma),
Penicillin-Streptomycin (15140, Gibco), and Amphotericin B (17-936E, Lonza). For culture
of YUMM1.7, YUMM3.3 and YUMMER1.7 cells, DMEM/F-12 medium supplemented with L-
Glutamine, 15mM HEPES (11330, Gibco), 10 % FBS, Penicillin-Streptomycin, Amphotericin
B, and 1 % non-essential amino acids (111400, Gibco) was used. Intermittent PCR testing
according to standard protocols was performed to rule out contamination with mycoplasma
(Young et al., 2010).
7.8 Quantitative real-time PCR
Total RNA from cells cultured in triplicates was isolated with the Total RNA Purification Kit (17200,
Norgen Biotek). The SuperScript III First-Strand Synthesis System (18080051, ThermoFisher)
was used to reverse-transcribe 1 µg of total RNA into cDNA according to the manufacturer’s
instructions using oligo(dT) primers. Subsequently, quantitative real-time PCR was performed
using Fast SYBR Green Master Mix (Applied Biosystems) and an Applied Biosystems 7900HT
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system. Expression of Apoe was normalized to Gapdh expression for each sample. Primer
sequences are listed in Table 7.2.
Table 7.2. Oligonucleotides for qRT-PCR.
Target Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
Apoe CTG ACA GGA TGC CTA GCC G CGC AGG TAA TCC CAG AAG C
Gapdh GCA CAG TCA AGG CCG AGA AT GCC TTC TCC ATG GTG GTG AA
7.9 Isolation of tumor-infiltrating leukocytes
To isolate tumor-infiltrating leukocytes, YUMM1.7 tumors were resected on day 21 after injection
and thoroughly minced on ice using scalpels. Tumor pieces were incubated in HBSS2+ (HBSS
with Calcium and Magnesium (24020, Gibco) supplemented with 2 % FBS, 1 mM sodium
pyruvate (11360, Gibco), 25 mM HEPES (15630, Gibco), 500 U/mL Collagenase IV (LS004188,
Worthington), 100 U/mL Collagenase I (LS004196, Worthington), and 0.2 mg/mL DNAse I
(10104159001, Roche)) for 30 minutes at 37°C on an orbital shaker (80 rpm). After thorough
trituration, the mixture was passed through a 70 µm strainer and diluted with HBSS2- (HBSS
without Calcium and Magnesium (14170, Gibco), 2 % FBS, 1 mM sodium pyruvate, and 25
mM HEPES). After centrifugation, the cell pellet was resuspended in a 35 % Percoll solution
(170891, GE Healthcare) and a phase of 70 % Percoll was underlaid using a glass Pasteur
pipette. The resulting gradient was centrifuged at 800×g for 20 minutes at room temperature
without brakes. After removal of the red blood cell-containing pellet on the bottom and excess
buffer containing cellular debris on the top, the cell population at the Percoll interphase enriched
for tumor-infiltrating leukocytes was washed twice with HBSS2-.
7.10 Flow cytometry
Unless otherwise mentioned, all steps were performed on ice and under protection from light.
Fc receptors were blocked by incubation with 2.5 µg/mL anti-CD16/32 antibody (clone 93;
101320, BioLegend) in staining buffer (25 mM HEPES, 2 % FBS, 10 mM EDTA (351-027,
Quality Biological), and 0.1 % sodium azide (7144.8-16, Ricca) in PBS) for 10 minutes. Cells
were incubated with antibodies diluted in staining buffer for 20 minutes, washed with PBS,
incubated with Zombie NIR Fixable Live/Dead Stain (423105, BioLegend) for 20 minutes at
room temperature, and washed twice with staining buffer. Cells were analyzed on an LSR
Fortessa (BD Biosciences). For cell quantification, CountBright counting beads (C36950,
Thermo Fisher) were added to the samples before analysis.
For intracellular staining of cytokines, cells were incubated with 500 ng/mL ionomycin (I0634,
Sigma), 100 ng/mL Phorbol 12-myristate 13-acetate (P8139, Sigma), and 10 µg/mL Brefeldin
A (B7651, Sigma) for 3-4 hours at 37°C prior to surface labelling and live/dead staining as
described above. Cells were then incubated in fixation/permeabilization buffer (00-5523,
eBioscience) for 30 minutes, washed with permeabilization buffer (00-5523, eBioscience), and
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incubated with antibodies diluted in permeabilization buffer for 20 minutes. Finally, cells were
washed with permeabilization buffer and subsequently with staining buffer.
7.11 Single cell RNA-sequencing of tumor-infiltrating leukocytes
Human APOE knock-in mice (n = 6 per group) were subcutaneously injected with 1 × 105
YUMM1.7 cells on the flank (mixed 1:1 with growth factor reduced Matrigel (356231, Corning)).
Tumors were resected on day 19 after injection and tumor-infiltrating leukocytes were isolated
as outlined above. Fc receptors were blocked with anti-CD16/32 antibody (clone 93; 101320
BioLegend) and cells were stained with an anti-CD45 antibody and DAPI in flow cytometry buffer
without sodium azide. Subsequently, 10,000 CD45+/DAPI- leukocytes from each mouse were
independently sorted on a BD FACSAria II cell sorter and samples from the same genotype
were pooled (i.e., total of 60,000 cells per genotype). Five-thousand cells per genotype were
targeted for single-cell RNA-sequencing (scRNAseq) on a Chromium Single Cell System (10x
Genomics). Samples were processed as per the manufacturer’s instructions (Chromium single
cell 3’ reagents, v3 chemistry) and libraries were sequenced on an Illumina NextSeq sequencer.
Pre-processing of sequencing results to generate transcript matrices was performed using
the 10x genomics Cell Ranger pipeline with default settings (v3.0.1). Further downstream
analysis was performed in R using the Seurat package v3.0.2. Cells were excluded if fewer than
200 or more than 6000 genes were detected, or if mitochondrial transcripts accounted for more
than 10 % of reads; genes were excluded if they were detected in fewer than five cells. The two
datasets were integrated using Seurat’s default settings, resulting in an expression matrix of
10,050 cells by 15,495 genes. Data were scaled and principal component analysis performed
using Seurat’s default settings. Cells were clustered using the FindNeighbors (20 dimensions
of reduction) and FindClusters functions at default settings; uniform manifold approximation
and projection (UMAP) was calculated for visualizing clusters. Differential gene expression
analysis between each cluster was performed using a Wilcoxon rank sum test. The identity of
cell clusters was determined by cross-referencing top differentially expressed transcripts with
the immunological genome project (Yoshida et al., 2019)(Figure 3.4). The identity of one cell
cluster remained ambiguous; since further sub-clustering revealed the presence of a mixed
population (data not shown), this cluster was labeled “diverse”.
For gene set enrichment analysis (GSEA), differential expression of genes between APOE4
and APOE2 for each cluster was calculated using a Wilcoxon rank sum test and genes were
ranked using the metric [-log10(p-value)]/[sign of log-fold change]. The ranked gene list was
used for calculating GSEA using the clusterProfiler package with the Hallmark gene sets in the
MSigDB database (Yu et al., 2012; Subramanian et al., 2005). For visualization, the number of
clusters with significant enrichment were plotted for pathways that were significant in more than
three clusters. For lineage summarization, all macrophage, monocyte, MDSC, basophil, and
mast cell clusters were grouped as “myeloid”, T cell, B cell, and NK clusters as “lymphoid”, all
DC clusters as “DCs”, and the remaining clusters as “other”.
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7.12 Antibodies
The following anti-mouse fluorophore-conjugated antibodies were used for flow cytometry:
CD45-BV785 (clone: 30-F11, cat#: 103149, supplier: BioLegend, dilution: 1:3,000), B220-
BUV395 (RA3-6B2, 563793, BD Biosciences, 1:400), CD11b-BV605 (M1/70, 101257, BioLe-
gend, 1:6,000), CD11b-FITC (M1/70, 101206, BioLegend, 1:4,000), Ly6G-PerCP/Cy5.5 (1A8,
127616, Biolegend, 1:500), Ly6C-BV711 (HK1.4, 128037, BioLegend, 1:12,000), I-A/I-E-BV421
(M5/114.15.2, 107632, BioLegend, 1:9,000), F4/80-FITC (BM8, 123108, BioLegend, 1:500),
CD24-PE (M1/69, 101808, BioLegend, 1:5,000), CD103-APC (2E7, 121414, BioLegend, 1:500),
CD19-FITC (1D3/CD19, 152404, BioLegend, 1:1,500), TCRβ-PerCP/Cy5.5 (H57-597, 109228,
BioLegend, 1:200), CD49b-APC (HMa2, 103516, BioLegend, 1:300), CD4-BV605 (GK1.5,
100451, BioLegend, 1:200), CD8α-AF700 (53-6.7, 100730, BioLegend, 1:1,000), Granzyme B-
PE (QA16A02, 372208, BioLegend, 1:200), IFNγ-PE/Cy7 (XMG1.2, 25-7311-82, eBioscience,
1:500).
7.13 Immunofluorescence microscopy
YUMM1.7 tumors were excised and fixed in 4 % paraformaldehyde at 4°C for 24 hours. Fixed
tumors were embedded in paraffin and sectioned in 5 µm thick slices. Sections were dewaxed
and rehydrated by incubation with xylene and descending ethanol concentrations. Antigen
retrieval was performed by microwaving samples in citrate buffer (C9999, Sigma) for 30 minutes.
Samples were blocked by incubation with 5 % goat serum in PBST (PBS with 0.1 % Tween-20)
for one hour. Subsequently, the sections were stained with anti-Endomucin (clone V.7C7, Santa
Cruz; 1:200 in PBST with 5 % goat serum) or anti-CD8 antibody (rabbit polyclonal, Synaptic
Systems, 1:200 in PBST with 5 % goat serum) at 4°C overnight. Slides were washed three times
with PBS and stained with AF555-conjugated anti-rat or AF488-conjugated anti-rabbit antibody
(1:200 in PBST, ThermoFisher Scientific) for 45 minutes. Slides were washed with PBS and
nuclei were counterstained with DAPI (2.5 µg/ml, Roche) before mounting with Prolong Gold
(ThermoFisher Scientific). Images of tumor sections were acquired using an RS-G4 confocal
microscope (Caliber I.D.). Images were quantified using CellProfiler (v3.1.8). Four sections per
tumor were analyzed and averaged. Samples without addition of primary antibody served as
negative controls.
7.14 Analysis of APOE genotype in the TCGA-SKCM study
To assess APOE genotypes in patients with melanoma, aligned whole exome sequencing
BAM files sliced for the genomic coordinates chr19:44904748-44910394 (GRCh38) were
downloaded from the TCGA-SKCM project using the Genomic Data Commons API (The
Cancer Genome Atlas Network, 2015). APOE variants were called using the samtools/bcftools
package, providing allele frequencies for chr19:44908684 (rs429358) and chr19:44908822
(rs7412) as determined in the Atherosclerosis Risk in Communities (ARIC) study (Blair et al.,
2005) as a prior distribution. Normal tissue samples (either blood, solid tissue, or buccal cells)
were available for 470 patients. No genotype could be determined in 10 patients. Additionally,
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patients that exhibited the APOE2;APOE4 genotype (n = 5) were excluded from analyses except
for genotype frequency assessment. APOE genotype abundance in the normal population was
based on the assessment of Caucasian patients in the ARIC study.
Clinical data including survival times and clinical response were used as recently curated (Liu
et al., 2018). The R package ‘TCGAbiolinks’ was used to add clinical data for Breslow depth
and Clark level. To assess the impact of APOE genotypes on survival, Kaplan-Meier survival
analyses were performed, and statistical significance was assessed with the log-rank test using
the ‘survival’ and ‘survminer’ packages. Hazard ratios were calculated according to a Cox
proportional hazards regression model using the ‘survival’ R package. For multivariate analysis,
variables found to be significantly associated with survival in univariate analysis were tested
for significance in a multivariate Cox proportional hazard model. For visualization purposes,
survival data were truncated at 12 years. All analyses were performed using R v3.5 (The R
Foundation for Statistical Computing) and RStudio v1.1.3.
7.15 Analysis of APOE genotype in the MDACC melanoma study
GWAS genotyping results of the MDACC melanoma study (Amos et al., 2011) were downloaded
from dbGap, and the APOE variant-defining SNPs rs429358 and rs7412 were selected using
Plink. Genotyping data were filtered to exclude variants with minor allele frequency < 1 %,
genotyping rate < 95 %, and departure from the Hardy-Weinberg equilibrium at P < 1E-06.
Samples were excluded if the missing genotype call rate exceeded 5 %. Genomic coordinates
were lifted from genome assembly hg18 to hg19 using the UCSC liftOverPlink utility, and
strands were aligned using GenotypeHarmonizer and the 1000 genomes reference genome.
Since no individual was found to exhibit the minor allele at rs429358, inadequate genotyping
at this locus was assumed as described by others (Radmanesh et al., 2014), prompting us
to impute the genotype at this locus based on a previously validated approach (Radmanesh
et al., 2014) prior to performing survival analysis. Pre-phasing was performed using ShapeIt v2,
and variants in the genomic region 19:45411941-45422946 were imputed using Impute2 with
parameters as suggested specifically for APOE imputation (-NE 20000 -iter 100 -call_thresh 0.8
-align_by_maf_g) (Radmanesh et al., 2014). Subsequent analysis of the association between
clinical variables and APOE genotype was performed as described for the TCGA-SKCM study
above.
7.16 Analysis of APOE genotype in the anti-PD1 melanoma studies by
Riaz et al. and Roh et al.
Analyses of the Roh et al. (Roh et al., 2017) and Riaz et al. (Riaz et al., 2017) studies were per-
formed as described for the TCGA-SKCM study. In brief, normal tissue whole-exome sequenc-
ing data were downloaded from dbGaP (BioProject IDs PRJNA369259 and PRJNA359359)
and APOE genotype was called as detailed above. No genotype could be determined from
the normal tissue sample of one patient in the Roh et al. study. For the Roh et al. study, only
patients that received both anti-CTLA4 and anti-PD1 treatment were considered. In the Riaz
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et al. study, patients were stratified by prior CTLA4 treatment status. Kaplan-Meier survival
analyses were performed using the ‘survival’ and ‘survminer’ packages, as detailed above.
7.17 Statistical analysis
Unless otherwise noted, all data are expressed as mean ± standard error of the mean. Groups
were compared using tests for significance as indicated in the figure legends and the text. A
significant difference was concluded at P < 0.05. Throughout all figures: *P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001. Unless indicated otherwise, all box plots show median, first
and third quartiles, and whiskers represent minimum and maximum.
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8 Publications
Parts of this thesis were published in:
OSTENDORF BN, BILANOVIC J, ADAKU N, TAFRESHIAN KN, TAVORA B, VAUGHAN RD, AND
TAVAZOIE SF. Common germline variants of the human APOE gene modulate melanoma
progression and survival. Nature Medicine, in press, 2020.
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